Form 4: ALX Oncology CFO Harish Shantharam Reports Stock Option Grant

Harish Shantharam, CFO of ALX Oncology Holdings Inc, reports the acquisition of stock options.

Summary

• On April 11, 2025, Harish Shantharam, the Chief Financial Officer of ALX Oncology Holdings Inc, was granted employee stock options.
• These options allow him to purchase 125,000 shares of ALX Oncology's common stock at an exercise price of $0.49 per share.
• The options vest on April 11, 2026, and expire on April 11, 2035.
• Following this transaction, Shantharam directly owns derivative securities for 125,000 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for management.

Positives

• The grant of stock options to the CFO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with those of shareholders. This grant is a standard component of executive compensation packages.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation in the biotech industry.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options as part of their executive compensation packages.
• The vesting schedule and exercise price are generally aligned with industry norms to incentivize long-term performance.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the CFO's performance leads to improved company results.

Key Dates

Keywords

ALX Oncology, Stock Options, Form 4, CFO, Harish Shantharam, Beneficial Ownership, Equity Securities